IL124792A - Compositions and kits containing bismuth and one or more antimicrobials, for the treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria - Google Patents

Compositions and kits containing bismuth and one or more antimicrobials, for the treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria

Info

Publication number: IL124792A
Authority: IL; Israel
Prior art keywords: bismuth; milligrams; antimicrobials; administration; days
Prior art date: 1995-12-07

Application number

IL12479296A

Other languages

English (en)

Other versions

IL124792A0 (en

Original Assignee

Procter & Gamble

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-07

Filing date

1996-11-22

Publication date

2004-01-04

1996-11-22 Application filed by Procter & Gamble filed Critical Procter & Gamble

1999-01-26 Publication of IL124792A0 publication Critical patent/IL124792A0/xx

2004-01-04 Publication of IL124792A publication Critical patent/IL124792A/en

Links

229910052797 bismuth Inorganic materials 0.000 title claims abstract description 65
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 title claims abstract description 65
239000004599 antimicrobial Substances 0.000 title claims abstract description 47
239000000203 mixture Substances 0.000 title claims abstract description 37
241000195493 Cryptophyta Species 0.000 title claims abstract description 29
208000018522 Gastrointestinal disease Diseases 0.000 title claims abstract description 27
241000192700 Cyanobacteria Species 0.000 title claims abstract description 26
238000011282 treatment Methods 0.000 title claims abstract description 23
230000001404 mediated effect Effects 0.000 title claims abstract description 16
208000010643 digestive system disease Diseases 0.000 claims abstract description 15
208000018685 gastrointestinal system disease Diseases 0.000 claims abstract description 15
230000000845 anti-microbial effect Effects 0.000 claims description 20
ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 claims description 8
229960000782 bismuth subsalicylate Drugs 0.000 claims description 8
239000004098 Tetracycline Substances 0.000 claims description 7
229960000282 metronidazole Drugs 0.000 claims description 7
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 7
235000019364 tetracycline Nutrition 0.000 claims description 7
150000003522 tetracyclines Chemical class 0.000 claims description 7
KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 claims description 6
229930182555 Penicillin Natural products 0.000 claims description 6
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 6
229960003159 atovaquone Drugs 0.000 claims description 6
KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 claims description 6
SULICOHAQXOMED-YDXPQRMKSA-H dibismuth;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Bi+3].[Bi+3].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O SULICOHAQXOMED-YDXPQRMKSA-H 0.000 claims description 6
239000002552 dosage form Substances 0.000 claims description 6
229960000564 nitrofurantoin Drugs 0.000 claims description 6
NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 6
150000001622 bismuth compounds Chemical class 0.000 claims description 5
229960002180 tetracycline Drugs 0.000 claims description 5
229930101283 tetracycline Natural products 0.000 claims description 5
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 4
241000192710 Microcystis aeruginosa Species 0.000 claims description 4
229940104825 bismuth aluminate Drugs 0.000 claims description 4
229960003722 doxycycline Drugs 0.000 claims description 4
PDSAKIXGSONUIX-UHFFFAOYSA-N hexaaluminum;dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Bi+3].[Bi+3] PDSAKIXGSONUIX-UHFFFAOYSA-N 0.000 claims description 4
229940049954 penicillin Drugs 0.000 claims description 4
229910000014 Bismuth subcarbonate Inorganic materials 0.000 claims description 3
241000195649 Chlorella <Chlorellales> Species 0.000 claims description 3
HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 3
229960003022 amoxicillin Drugs 0.000 claims description 3
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 3
229960000723 ampicillin Drugs 0.000 claims description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 claims description 3
229940036358 bismuth subcarbonate Drugs 0.000 claims description 3
229960004645 bismuth subcitrate Drugs 0.000 claims description 3
ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 claims description 3
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 3
229960005053 tinidazole Drugs 0.000 claims description 3
-1 ampiciUin Chemical compound 0.000 claims 2
241000192542 Anabaena Species 0.000 claims 1
241000192660 Aphanizomenon Species 0.000 claims 1
244000085413 Aphanizomenon flos aquae Species 0.000 claims 1
235000013781 Aphanizomenon flos aquae Nutrition 0.000 claims 1
241000192534 Dolichospermum flos-aquae Species 0.000 claims 1
241000192117 Trichodesmium erythraeum Species 0.000 claims 1
229940054349 aphanizomenon flos-aquae Drugs 0.000 claims 1
238000000034 method Methods 0.000 abstract description 25
230000002265 prevention Effects 0.000 abstract description 9
241001465754 Metazoa Species 0.000 abstract 2
208000015181 infectious disease Diseases 0.000 description 11
206010012735 Diarrhoea Diseases 0.000 description 7
150000001621 bismuth Chemical class 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000002550 fecal effect Effects 0.000 description 6
239000003242 anti bacterial agent Substances 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
241000206751 Chrysophyceae Species 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
241000195628 Chlorophyta Species 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
206010061598 Immunodeficiency Diseases 0.000 description 3
241000199919 Phaeophyceae Species 0.000 description 3
241000206572 Rhodophyta Species 0.000 description 3
239000003096 antiparasitic agent Substances 0.000 description 3
229940125687 antiparasitic agent Drugs 0.000 description 3
239000003904 antiprotozoal agent Substances 0.000 description 3
239000003086 colorant Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000000694 effects Effects 0.000 description 3
229960003276 erythromycin Drugs 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 2
241000251468 Actinopterygii Species 0.000 description 2
241000206761 Bacillariophyta Species 0.000 description 2
241000589876 Campylobacter Species 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
201000009840 acute diarrhea Diseases 0.000 description 2
229940126575 aminoglycoside Drugs 0.000 description 2
230000000842 anti-protozoal effect Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
235000013365 dairy product Nutrition 0.000 description 2
229960000691 diiodohydroxyquinoline Drugs 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
UXZFQZANDVDGMM-UHFFFAOYSA-N iodoquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(I)C2=C1 UXZFQZANDVDGMM-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000003120 macrolide antibiotic agent Substances 0.000 description 2
229940041033 macrolides Drugs 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
150000002960 penicillins Chemical class 0.000 description 2
229940101070 pepto-bismol Drugs 0.000 description 2
230000000243 photosynthetic effect Effects 0.000 description 2
229960000611 pyrimethamine Drugs 0.000 description 2
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229940040944 tetracyclines Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 1
GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
241000512259 Ascophyllum nodosum Species 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241001442195 Bangia Species 0.000 description 1
241001488115 Catenella Species 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
239000004099 Chlortetracycline Substances 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
241000006460 Cyana Species 0.000 description 1
241001464430 Cyanobacterium Species 0.000 description 1
208000005156 Dehydration Diseases 0.000 description 1
241000199914 Dinophyceae Species 0.000 description 1
241000218614 Dinophysis acuminata Species 0.000 description 1
241000507812 Dinophysis norvegica Species 0.000 description 1
208000015877 Duodenal disease Diseases 0.000 description 1
206010014418 Electrolyte imbalance Diseases 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
240000008415 Lactuca sativa Species 0.000 description 1
WESWYMRNZNDGBX-YLCXCWDSSA-N Mefloquine hydrochloride Chemical compound Cl.C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 WESWYMRNZNDGBX-YLCXCWDSSA-N 0.000 description 1
241000237852 Mollusca Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
241000180701 Nitzschia <flatworm> Species 0.000 description 1
239000004100 Oxytetracycline Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930195708 Penicillin V Natural products 0.000 description 1
241001377010 Pila Species 0.000 description 1
108010040201 Polymyxins Proteins 0.000 description 1
241000206609 Porphyra Species 0.000 description 1
241000220010 Rhode Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
241000206764 Xanthophyceae Species 0.000 description 1
208000019790 abdominal distention Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000004075 alteration Effects 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
NNBFNNNWANBMTI-UHFFFAOYSA-M brilliant green Chemical compound OS([O-])(=O)=O.C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 NNBFNNNWANBMTI-UHFFFAOYSA-M 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
229960000603 cefalotin Drugs 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
229940106164 cephalexin Drugs 0.000 description 1
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960002328 chloroquine phosphate Drugs 0.000 description 1
CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
229960004475 chlortetracycline Drugs 0.000 description 1
CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
229960002227 clindamycin Drugs 0.000 description 1
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
238000004040 coloring Methods 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
208000018595 duodenum disease Diseases 0.000 description 1
208000001848 dysentery Diseases 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000013505 freshwater Substances 0.000 description 1
229960001625 furazolidone Drugs 0.000 description 1
PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
229960005329 mefloquine hydrochloride Drugs 0.000 description 1
229960000901 mepacrine Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
229960004918 nimorazole Drugs 0.000 description 1
MDJFHRLTPRPZLY-UHFFFAOYSA-N nimorazole Chemical compound [O-][N+](=O)C1=CN=CN1CCN1CCOCC1 MDJFHRLTPRPZLY-UHFFFAOYSA-N 0.000 description 1
IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
229960001907 nitrofurazone Drugs 0.000 description 1
229960001180 norfloxacin Drugs 0.000 description 1
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
229960001699 ofloxacin Drugs 0.000 description 1
229960000625 oxytetracycline Drugs 0.000 description 1
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
235000019366 oxytetracycline Nutrition 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
229940056367 penicillin v Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000029553 photosynthesis Effects 0.000 description 1
238000010672 photosynthesis Methods 0.000 description 1
230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
208000028172 protozoa infectious disease Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
235000012045 salad Nutrition 0.000 description 1
235000014102 seafood Nutrition 0.000 description 1
235000015170 shellfish Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960005404 sulfamethoxazole Drugs 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
235000003563 vegetarian diet Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL12479296A 1995-12-07 1996-11-22 Compositions and kits containing bismuth and one or more antimicrobials, for the treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria IL124792A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/569,029 US5744168A (en)	1995-12-07	1995-12-07	Methods and compositions for the prevention and treatment of gastrointestinal disorders
PCT/US1996/018652 WO1997020565A1 (en)	1995-12-07	1996-11-22	Compositions, containing bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders

Publications (2)

Publication Number	Publication Date
IL124792A0 IL124792A0 (en)	1999-01-26
IL124792A true IL124792A (en)	2004-01-04

Family

ID=24273803

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12479296A IL124792A (en)	1995-12-07	1996-11-22	Compositions and kits containing bismuth and one or more antimicrobials, for the treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria

Country Status (17)

Country	Link
US (1)	US5744168A (de)
EP (1)	EP0865284B1 (de)
AT (1)	ATE231726T1 (de)
BR (1)	BR9612123A (de)
CA (1)	CA2239423C (de)
CO (1)	CO4940459A1 (de)
DE (1)	DE69626036T2 (de)
DK (1)	DK0865284T3 (de)
ES (1)	ES2191776T3 (de)
IL (1)	IL124792A (de)
MX (1)	MX9804577A (de)
MY (1)	MY113635A (de)
NO (1)	NO319386B1 (de)
PT (1)	PT865284E (de)
TR (1)	TR199801024T2 (de)
TW (1)	TW445143B (de)
WO (1)	WO1997020565A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9224739D0 (en) *	1992-11-26	1993-01-13	Wellcome Found	Medicaments
ES2346955T3 (es) *	2001-08-08	2010-10-22	Btg International Limited	Espuma inyectable y aplicaciones farmaceuticas novedosas de la misma.
FR2962684B1 (fr)	2010-07-13	2012-08-24	Oberthur Technologies	Procede de realisation d'un motif sur un support avec une encre de securite

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR962163A (de) *		1950-06-02
US4049817A (en) *	1972-08-14	1977-09-20	Sandoz Ltd.	Synergistic compositions
US4514421A (en) *	1979-08-30	1985-04-30	Herschler R J	Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it
WO1986005981A1 (en) *	1985-04-18	1986-10-23	Borody Thomas J	Treatment of non-ulcer dyspepsia with bismuth salts
US5256684A (en) *	1985-06-13	1993-10-26	The Procter & Gamble Company	Methods and compositions for the treatment of gastrointestinal disorders
DE3650504T2 (de) *	1985-06-13	1996-10-31	Marshall Barry James	Verfahren und Zusammensetzungen zur Behandlung von gastrointestinalen Störungen
JPS63174926A (ja) *	1987-01-09	1988-07-19	Nitto Kasei Kk	家禽用抗コクシジウム剤
IL85472A (en) *	1987-03-09	1991-06-30	Procter & Gamble	Pharmaceutical compositions for treating gastrointestinal disorders
JP2733849B2 (ja) *	1987-10-12	1998-03-30	ボロディー，ソーマス・ユリウス	胃腸障害治療のための改良された方法
EP0375068A1 (de) *	1988-12-23	1990-06-27	Gist-Brocades N.V.	Mischungen von Bismuth-Verbindungen und Tetracyclinen
US5221664A (en) *	1990-04-23	1993-06-22	Magainin Pharmaaceuticals Inc.	Composition and treatment with biologically active peptides and toxic cations
KR100193933B1 (ko) *	1990-07-20	1999-06-15	에밀리오 캠포레시, 존 페르구손	비스무트와 폴리아크릴레이트와의 수용성 착체, 이의 제조 방법 및 상기 착체 또는 다른 비스무트염을 함유하는 궤양성 대장염 치료용 약제학적 조성물
EP0624373B1 (de) *	1993-05-11	1999-09-08	Spirig Ag Pharmazeutische Präparate	Festes bismut- und amoxycillinhaltiges Arzneipräparat und seine Verwendung
AUPM596894A0 (en) *	1994-05-30	1994-06-23	Hybrid Scientific Pty Ltd	Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders

1995
- 1995-12-07 US US08/569,029 patent/US5744168A/en not_active Expired - Fee Related
1996
- 1996-11-22 DE DE69626036T patent/DE69626036T2/de not_active Expired - Fee Related
- 1996-11-22 TR TR1998/01024T patent/TR199801024T2/xx unknown
- 1996-11-22 WO PCT/US1996/018652 patent/WO1997020565A1/en not_active Ceased
- 1996-11-22 BR BR9612123A patent/BR9612123A/pt not_active Application Discontinuation
- 1996-11-22 DK DK96940568T patent/DK0865284T3/da active
- 1996-11-22 AT AT96940568T patent/ATE231726T1/de not_active IP Right Cessation
- 1996-11-22 ES ES96940568T patent/ES2191776T3/es not_active Expired - Lifetime
- 1996-11-22 PT PT96940568T patent/PT865284E/pt unknown
- 1996-11-22 EP EP96940568A patent/EP0865284B1/de not_active Expired - Lifetime
- 1996-11-22 IL IL12479296A patent/IL124792A/en not_active IP Right Cessation
- 1996-11-22 CA CA002239423A patent/CA2239423C/en not_active Expired - Fee Related
- 1996-12-04 CO CO96063581A patent/CO4940459A1/es unknown
- 1996-12-07 MY MYPI96005154A patent/MY113635A/en unknown
- 1996-12-26 TW TW085116051A patent/TW445143B/zh active
1998
- 1998-06-08 MX MX9804577A patent/MX9804577A/es unknown
- 1998-06-08 NO NO19982635A patent/NO319386B1/no unknown

Also Published As

Publication number	Publication date
PT865284E (pt)	2003-06-30
CA2239423A1 (en)	1997-06-12
CO4940459A1 (es)	2000-07-24
ATE231726T1 (de)	2003-02-15
DK0865284T3 (da)	2003-05-19
BR9612123A (pt)	1999-02-17
TW445143B (en)	2001-07-11
MX9804577A (es)	1998-10-31
TR199801024T2 (xx)	1998-09-21
EP0865284B1 (de)	2003-01-29
NO319386B1 (no)	2005-08-08
DE69626036T2 (de)	2004-01-22
WO1997020565A1 (en)	1997-06-12
DE69626036D1 (de)	2003-03-06
IL124792A0 (en)	1999-01-26
NO982635D0 (no)	1998-06-08
ES2191776T3 (es)	2003-09-16
MY113635A (en)	2002-04-30
NO982635L (no)	1998-08-04
US5744168A (en)	1998-04-28
CA2239423C (en)	2003-04-01
EP0865284A1 (de)	1998-09-23

Legal Events

Date	Code	Title
2004-06-01	FF	Patent granted
2004-06-20	KB	Patent renewed
2007-07-24	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
FI100168B (fi)	1997-10-15	Menetelmä suun kautta annettavan farmaseuttisen valmisteen valmistamis eksi
DE3650787T2 (de)	2006-11-16	Pharmazeutische Zusammensetzung zur Behandlung gastrointestinaler Beschwerden, die Wismut und ein antimikrobielles Mittel enthält
AU590578B2 (en)	1989-11-09	Treatment of non-ulcer dyspepsia with bismuth salts
JPH09241173A (ja)	1997-09-16	乳酸菌を有効成分とする抗胃炎剤、抗潰瘍剤および醗酵食品
KR100282166B1 (ko)	2001-02-15	약학적 박테리오신 조성물
KR0145553B1 (ko)	1998-08-17	클로스트리듐 디피실레 하리증 및 위막성 대장염의 예방 및 치료용 의약조성물
US5866150A (en)	1999-02-02	Antibacterially active extracts from the marine algae chaetoceros and methods of use
US5744168A (en)	1998-04-28	Methods and compositions for the prevention and treatment of gastrointestinal disorders
CA2136936A1 (en)	1995-05-31	Moenomycin and its derivatives for the production of pharmaceuticals, and pharmaceuticals containing moenomycin or its derivatives
EP0865287B1 (de)	2002-02-27	Bismut enthaltende zusammensetzungen zur verhütung und behandlung gastrointestinaler beschwerden
Nusbaum et al.	1981	Action of selected antibiotics on four common bacteria associated with diseases of fish
FR2550707A1 (fr)	1985-02-22	Medicament immunomodulateur d'origine biologique et son procede de preparation
FR2472389A1 (fr)	1981-07-03	Compositions antibiotiques contenant un macrolide et un aminoheteroside
WO1996035436A1 (en)	1996-11-14	Compositions comprising bismuth and one or more antimicrobials, for the treatment and prevention of gastrointestinal disorders
Andersen et al.	1980	Pivmecillinam in the treatment of therapy resistant urinary tract infections: A comparison with pivmecillinam, pivampicillin and their combination
CA2239420C (en)	2003-03-18	Compositions, comprising bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders
AU6415698A (en)	1999-10-18	The process for the preparation of a stable fixed dose pharmaceutical composition of anti infective agent/agents and micro organisms as active ingredients
Goodwin et al.	1988	Differences between in vitro and in vivo sensitivity of Campylobacter pylori to antibacterials
KR20010077797A (ko)	2001-08-20	위장 질환 개선을 위한 천연 항균물질 조성물
Kırmusaoğlu et al.	2007	Effects of fermented sumach on the formation of slime layer of staphylococcus aureus
US20020025309A1 (en)	2002-02-28	Stable oral pharmaceutical formulation containing an anti-infective agent and a microorganism